Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL28798151 | 0.87 | NAPRT (0.45) | CA2TSHRUSP2TDP1NAPRT | |
| Pyridine SCHEMBL4307620 | 0.87 | NAPRT (0.45) | CA2TSHRUSP2TDP1NAPRT | |
| Pyridine SCHEMBL27970732 | 0.85 | NAPRT (0.43) | TSHRTDP1NAPRT | |
| Pyridine SCHEMBL27637980 | 0.85 | NAPRT (0.43) | TSHRTDP1NAPRT | |
| Pyridine SCHEMBL27637981 | 0.85 | NAPRT (0.43) | TSHRTDP1NAPRT | |
| Pyridine SCHEMBL28123986 | 0.85 | NAPRT (0.43) | TSHRTDP1NAPRT | |
| Pyridine SCHEMBL27926369 | 0.85 | NAPRT (0.43) | TSHRTDP1NAPRT | |
| Pyrimidine SCHEMBL3960330 | 0.81 | NAPRT (0.35) | CA2TSHRUSP2NAPRT | |
| SCHEMBL5991 | 0.80 | — | — | |
| SCHEMBL27259142 | 0.80 | TSHR (0.50) | CA2TSHRUSP2CA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104145022-B | Determine the tool and method of (D) 2 hydroxyl glutaric acid (D2HG) or (D) 2 hydroxyl adipic acid | 德国癌症研究中心 | 2017-07-11 | — | — | CN | claimed |
| CN-105753858-B | Heterocyclic compound and p27Kip1Decomposing inhibitor | ASKA制药株式会社 | 2019-04-30 | — | — | CN | disclosed |
| CN-109414446-A | Phospholipid compositions | 麦克哈弗特制药有限责任公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-107082805-A | The suppression of AXL signal transductions in anti-transfer therapy | 小利兰·斯坦福大学托管委员会 | 2017-08-22 | — | — | CN | disclosed |
| CN-104145022-B | Determine the tool and method of (D) 2 hydroxyl glutaric acid (D2HG) or (D) 2 hydroxyl adipic acid | 德国癌症研究中心 | 2017-07-11 | — | — | CN | disclosed |
| CN-105753858-A | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA制药株式会社 | 2016-07-13 | — | — | CN | disclosed |
| CN-102985405-B | Heterocyclic compounds and p27Kip1Decomposition inhibitor | ASKA制药株式会社 | 2016-07-06 | — | — | CN | disclosed |
| CN-103327972-A | Substituted benzamides and their uses | UNIV LELAND STANFORD JUNIOR | 2013-09-25 | — | — | CN | disclosed |
| CN-103313707-A | Application, synthesis method and pharmaceutical composition of diphenyl-amine derivative | FAES FARMA SA | 2013-09-18 | — | — | CN | disclosed |
| CN-102985405-A | Heterocyclic compounds and p27Kip1Decomposition inhibitor | ASKA PHARM CO LTD | 2013-03-20 | — | — | CN | disclosed |
| CN-1665792-A | Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant tumor diseases | ZENTARIS GMBH (DE) | 2005-09-07 | — | — | CN | disclosed |
| CN-1638800-A | Human monoclonal antibodies against CD30 | MEDAREX INC (US) | 2005-07-13 | — | — | CN | disclosed |
| CN-1551885-A | Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments | — | 2004-12-01 | — | — | CN | disclosed |
| CN-1443171-A | Novel heteroaryl derivatives and use thereof as pharmaceuticals | ZENTARIS AG (DE) | 2003-09-17 | — | — | CN | disclosed |
| CN-1443172-A | Novel heteroaryl derivatives and their use as medicaments | ZENTARIS AG (DE) | 2003-09-17 | — | — | CN | disclosed |
| EP-0800396-A4 | TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO INC (US) | 2000-06-28 | — | — | EP | disclosed |
| US-5962442-A | ADMINISTERING A 3-OXO-4-AZASTEROID | MERCK & CO., INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0800396-A1 | TREATMENT OF HYPERANDROGENIC CONDITIONS | Merck & Co., Inc. (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5656613-A | ADDUCT OF A 3-OXO-4-AZASTEROID AND NADPH | MERCK & CO., INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996020713-A1 | TREATMENT OF HYPERANDROGENIC CONDITIONS | MERCK & CO., INC. (US) | 1996-07-11 | — | — | WO | disclosed |